Edition:
India

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

59.17USD
23 May 2018
Change (% chg)

$0.72 (+1.23%)
Prev Close
$58.45
Open
$58.51
Day's High
$59.49
Day's Low
$58.43
Volume
3,376,158
Avg. Vol
3,729,062
52-wk High
$66.41
52-wk Low
$52.83

Chart for

About

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes... (more)

Overall

Beta: 0.83
Market Cap(Mil.): $176,050.70
Shares Outstanding(Mil.): 2,727.35
Dividend: 0.47
Yield (%): 2.91

Financials

  MRK.N Industry Sector
P/E (TTM): 35.16 30.95 32.75
EPS (TTM): 1.84 -- --
ROI: 6.58 14.84 14.38
ROE: 12.28 16.34 16.07

Merck's cancer drug Keytruda notches another trial success

Merck & Co said on Wednesday its drug Keytruda helped patients with a certain type of lung cancer live longer and prevented the disease from spreading, helping to solidify its position in the lucrative cancer market.

23 May 2018

UPDATE 2-Merck's cancer drug Keytruda notches another trial success

May 23 Merck & Co said on Wednesday its drug Keytruda helped patients with a certain type of lung cancer live longer and prevented the disease from spreading, helping to solidify its position in the lucrative cancer market.

23 May 2018

Merck's Keytruda succeeds late-stage lung cancer study

May 23 Merck & Co on Wednesday said its cancer drug Keytruda had met the main goals of a late-stage study testing it in combination with chemotherapy for a type of lung cancer.

23 May 2018

Merck's Keytruda boosts response in hard-to-treat lung cancer

The combination of Merck & Co's immunotherapy Keytruda and chemotherapy boosted response rates in patients with advanced hard-to-treat squamous cell lung cancer, the company said on Wednesday.

17 May 2018

Merck's Keytruda boosts response in hard-to-treat lung cancer

May 16 The combination of Merck & Co's immunotherapy Keytruda and chemotherapy boosted response rates in patients with advanced hard-to-treat squamous cell lung cancer, the company said on Wednesday.

17 May 2018

BRIEF-Oncosec Expands Relationship With Merck For Combination Of Immunopulse Il-12 And Keytruda

* ONCOSEC EXPANDS RELATIONSHIP WITH MERCK, ANNOUNCES CLINICAL COLLABORATION TO EVALUATE COMBINATION OF IMMUNOPULSE IL-12 AND KEYTRUDA FOR TRIPLE NEGATIVE BREAST CANCER

08 May 2018

BRIEF-Lynparza (Olaparib) Tablets Receive EU Approval For The Treatment Of Platinum-Sensitive Relapsed Ovarian Cancer

* LYNPARZA® (OLAPARIB) TABLETS RECEIVE EU APPROVAL FOR THE TREATMENT OF PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER

08 May 2018

BRIEF-Moderna And Merck Expand MRNA Cancer Vaccines Collaboration

* MODERNA AND MERCK EXPAND MRNA CANCER VACCINES COLLABORATION

04 May 2018

BRIEF-Merck Provides Update On Keynote-407 Trial

* MERCK - PHASE 3 KEYNOTE-407 TRIAL MET A PRE-SPECIFIED SECONDARY ENDPOINT OF ORR IN AN EARLY COHORT OF PARTICIPANTS AT AN INTERIM ANALYSIS

03 May 2018

UPDATE 1-Merck KGaA family says unreservedly behind the pharma unit

* Family backs pharma unit even if avelumab not a blockbuster

03 May 2018

Competitors

Earnings vs. Estimates